For use in patients with recurrent CDI at high risk of recurrence
The American Gastroenterological Association (AGA) has released the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, recommending fecal microbiota transplant (FMT) in most cases of recurrent Clostridioides difficile infection (CDI).
Specifically, the guideline recommends the use of FMT-based therapy in patients with recurrent CDI at high risk of recurrence following standard-of-care antibiotics and in hospitalized patients with severe CDI after standard-of-care antibiotics if there is no improvement. Of note, the AGA does not recommend FMT therapies for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS).
“Using fecal microbiota transplant, we take stool from a healthy donor and transfer it to the colon of the person with recurrent C. diff, restoring balance to their gut microbiome,” Anne Peery, MD, associate professor of medicine and director of the adult inpatient nutrition support team at the University of North Carolina School of Medicine, said in a press release. “FMT is a safe and effective treatment with enough scientific evidence to be offered to most patients with two or more C. diff recurrences.”
Continue to full article here.